Edgewise Therapeutics vs Tenax Therapeutics
EWTX and TENX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EWTX and TENX compare
Edgewise Therapeutics is the larger company, worth 82 times as much as Tenax Therapeutics ($5.0B against $60.6M).
Edgewise Therapeutics scores higher on the StockData Score (8 against 6 for Tenax Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EWTX | TENX |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $60.6M |
| Share price | $45.93 | $1.62 |
| Change, 1 year | 117% | −76.8% |
| Change, 5 years | 130% | −99.9% |
| Beta (5Y) | 1.47 | 0.62 |
| Employees | 146 | 14 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 5.6× | – |
| P/B | 3.1× | 0.6× (better) |
| FCF yield | −4.1% | – |
| Profitability | ||
| Return on equity | 92.1% (better) | −64.2% |
| Return on invested capital | −16.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.30 | 14.01 (better) |
| Altman Z-score | 21.41 (better) | −1.49 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 81.1% |
| Held by insiders | 20.0% | 4.8% |
| Insider net buying, 12 months | −$17.6M | $6.5M (better) |
| Short interest, % of float | 14.6% | 16.3% |
Go deeper
- EWTX stock overview
- EWTX income statement
- EWTX valuation and score
- TENX stock overview
- TENX income statement
- TENX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.